TriangleNCT00958841 · OUTCOME
Percentage of Responders With Probability of Success at Month 6 - Individual NETs
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- Not reported
- Time frame
- 6 months
What was measured
Percentage of responders for each of the 10 NET indications considered in the study. Responder analyses were performed for an indication only if there were at least 6 patients in the efficacy analyzable set. For all other individual indications, the numbers of patients in the efficacy analyzable sets were less than 6 and therefore no responder analyses were carried out for these indications. The probability of success was a chance that the true responder rate was greater than 15%) for the indications gastrinoma, prolactinoma, and Nelson's syndrome.
Analysis population: The efficacy analyzable set included all enrolled patients who received at least one dose of pasireotide LAR and had indication-specific baseline primary biochemical tumor marker levels \>ULN.
Groups in this outcome
Gastrinoma
One of the 10 types of PNETs analyzed
Prolactinoma
One of the 10 types of PNETs analyzed.
Nelson's Syndrome
based on disease specific primary biochemical tumor markers. Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
| Group | Source count |
|---|---|
| Gastrinoma | 13 |
| Prolactinoma | 37 |
| Nelson's Syndrome | 14 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Gastrinoma | 46.2 | Not reported | Not reported | Not reported | Not reported |
| Prolactinoma | 21.6 | Not reported | Not reported | Not reported | Not reported |
| Nelson's Syndrome | 50.0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 46.2
- group Id
- OG001
- value
- 21.6
- group Id
- OG002
- value
- 50.0
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 37
- group Id
- OG002
- value
- 14
- units
- Participants
- description
- Percentage of responders for each of the 10 NET indications considered in the study. Responder analyses were performed for an indication only if there were at least 6 patients in the efficacy analyzable set. For all other individual indications, the numbers of patients in the efficacy analyzable sets were less than 6 and therefore no responder analyses were carried out for these indications. The probability of success was a chance that the true responder rate was greater than 15%) for the indications gastrinoma, prolactinoma, and Nelson's syndrome.
- groups
- description
- One of the 10 types of PNETs analyzed
- id
- OG000
- title
- Gastrinoma
- description
- One of the 10 types of PNETs analyzed.
- id
- OG001
- title
- Prolactinoma
- description
- based on disease specific primary biochemical tumor markers. Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
- id
- OG002
- title
- Nelson's Syndrome
- param Type
- NUMBER
- population Description
- The efficacy analyzable set included all enrolled patients who received at least one dose of pasireotide LAR and had indication-specific baseline primary biochemical tumor marker levels \>ULN.
- reporting Status
- POSTED
- time Frame
- 6 months
- title
- Percentage of Responders With Probability of Success at Month 6 - Individual NETs
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice